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Abstract
Vitamin A can significantly decrease measles-associated morbidity and mortality. Vitamin A can inhibit the replication of
measles virus (MeV) in vitro through an RARa- and type I interferon (IFN)-dependent mechanism. Retinoid-induced gene I
(RIG-I) expression is induced by retinoids, activated by MeV RNA and is important for IFN signaling. We hypothesized that
RIG-I is central to retinoid-mediated inhibition of MeV in vitro. We demonstrate that RIG-I expression is increased in cells
treated with retinoids and infected with MeV. The central role of RIG-I in the retinoid-anti-MeV effect was demonstrated in
the Huh-7/7.5 model; the latter cells having non-functional RIG-I. RAR-dependent retinoid signaling was required for the
induction of RIG-I by retinoids and MeV. Retinoid signaling was also found to act in combination with IFN to induce high
levels of RIG-I expression. RIG-I promoter activation required both retinoids and MeV, as indicated by markers of active
chromatin. IRF-1 is known to be regulated by retinoids and MeV, but we found recruitment of IRF-1 to the RIG-I promoter by
retinoids alone. Using luciferase expression constructs, we further demonstrated that the IRF-1 response element of RIG-I
was required for RIG-I activation by retinoids or IFN. These results reveal that retinoid treatment and MeV infection induces
significant RIG-I. RIG-I is required for the retinoid-MeV antiviral response. The induction is dependent on IFN, retinoids and
IRF-1.
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Introduction
In 2007 measles was responsible for 197 000 deaths, the lowest
rate ever reported [1]. Although improved vaccine coverage is the
primary factor driving this change, increased survival of those
infected through the use of high dose vitamin A (retinol) has likely
made an important contribution. Morbidity and mortality due to
measles can be significantly reduced with two doses of retinol
(200,000 IU; water-based formulation) [2,3,4]. Since the mid-
1990s, the WHO and UNICEF have recommended vitamin A
treatment for acute measles in regions of the developing world
with high mortality rates [5].
Vitamin A, its synthetic derivatives and metabolites are
collectively referred to as retinoids [4]. Retinoids are required for
a wide-range of crucial biological processes including regulation of
embryonic development, maintenance of the integrity of epithelial
cell surfaces, vision and immunity [6]. The active retinol metabolite,
all trans retinoic acid (ATRA) is responsible for mediating many of
the important functions of retinoids. ATRA is the natural ligand for
the retinoic acid receptors (RARs), which form heterodimers with
the retinoid X receptors (RXRs) within the nucleus [7]. RAR-RXR
heterodimers bind to retinoid acid response elements (RAREs) on
the promoters of target genes to activate transcription of these genes
when bound by ligand [4].
Recent studies from our group have reported that ATRA can
inhibit measles virus (MeV) replication in vitro through a retinoid
nuclear receptor-dependent pathway [8]. Our studies further
showed that interferon (IFN) is necessary for this anti-viral effect,
and that initially uninfected bystander cells are protected from
subsequent viral infection by up regulating the expression of IFN-
stimulated genes (ISGs) [9]. Anti-MeV effects of retinoids have
been demonstrated in a number of primary human cells and cell
lines of diverse tissue origin [8] including myelomonocytic U937
cells that have been an important model for these molecular
studies.
Retinoids are implicated in regulating the expression of a
number of ISGs, including retinoid-induced gene I (RIG-I) and
IFN regulatory factor 1 (IRF-1) [10,11,12,13,14,15,16,17,18,19].
RIG-I is a pattern recognition receptor that can detect single-
stranded RNA [20,21,22]. RIG-I is expressed at a basal level in
many cell types. It can initiate the production of type I IFN and is
itself an ISG [23]. IFN has been reported to induce RIG-I
expression by causing the IRF-1 transcription factor to bind to the
RIG-I promoter [24].
The RIG-I ligand has been shown to be 59-triphosphorylated,
short single-stranded RNA [25], although other ligands have been
identified (reviewed in [26]). RIG-I has been shown to recognize a
variety of RNA viruses, including MeV [22]. To investigate the
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e22323requirement of RIG-I signaling in response to retinoids and MeV,
we used the Huh-7 cell line, which is derived from a human
hepatocellular carcinoma used extensively in hepatitis C virus
(HCV) research [27,28]. Of particular interest for our studies, an
Huh-7 subclone (Huh-7.5) that is permissive for HCV RNA
replication [28] has a transition point mutation of a C to T at
nucleotide 164 in the CARD domain of RIG-I rendering the
protein non-functional RIG-I [29,30].
RIG-I was originally identified as a retinoid-responsive gene by
treating NB4 cells with 1 mM of ATRA for 48 hours [10]. The
NB4 cell line is derived from acute promyelocytic leukemia (APL)
with a t(15:17) reciprocal translocation [31]. This translocation
fuses the PML gene with the retinoic acid receptor alpha (RARa)
generating a PML-RARa chimera [32,33,34,35,36]. The fusion
protein retains functional domains of RARa and has been shown
to be a ligand-dependent transcriptional activator of RAREs
[33,34,35]. A subclone of NB4 cells, NB4-MR4 (R4 cells), are
retinoic acid resistant due to a point mutation in the ligand-
binding domain of the fusion PML-RARa [37]. Mutant PML-
RARa proteins do not bind ligand but retain their ability to bind
to RAREs and block the transcription of retinoic acid responsive
genes in a dominant-negative fashion [37]. This model facilitated
investigation of the role of retinoid signaling in the induction of
RIG-I and the retinoid-induced anti-MeV state.
We hypothesize that RIG-I is essential for the retinoid mediated
anti-MeV response and that the inhibition of MeV requires both
RAR-RXR activity and an IFN signal [8,9].
Results
RIG-I expression is regulated by the combination of MeV
infection and ATRA treatment
We have previously shown that MeV can be inhibited in a
number of cells lines including U937 cells and PBMCs [8]. To
determine the involvement of RIG-I in the retinoid-mediated
inhibition of MeV, the regulation of RIG-I expression during
MeV infection with and without ATRA treatment was investigat-
ed in U937 cells. These cells are neoplastic and histiocytic
progenitors of monocytes that have been extensively used in
immunological studies [38]. They can be infected with MeV and
are partially responsive to pharmacological doses of retinoids [8].
RIG-I mRNA and protein are expressed at very low levels in
untreated U937 cells. MeV infection alone resulted in a small
increase in RIG-I mRNA, while ATRA treatment alone had no
discernible effect on RIG-I expression in this cell line. Importantly,
U937 cells infected with MeV and treated with increasing doses of
ATRA showed a dose response in RIG-I expression at the mRNA
level (Figure 1A) and increased expression at the protein level
(Figure 1B) over the induced over-expression of RIG-I by the
artificial treatment with exogenous IFNb. The IFNb (positive
control) could induce RIG-I expression as expected (Figure 1A).
The combination of ATRA and IFNb treatment resulted in higher
levels of RIG-I expression than IFNb alone (Figure 1A).
Additionally, in our system we observe the up-regulation of a
number of ISGs including IRF-7 [9] and MDA-5 (data not
shown). RIG-I and MDA-5 have both been implicated in the
induction of IFN in response to MeV [39]. The importance of
RIG-I in this antiviral response due to its regulation by retinoids.
To date, there has been no evidence that MDA-5 is a retinoid
responsive gene.
RIG-I necessary for anti-viral effect of retinoids
RIG-I is an interferon-stimulated gene (ISG) involved in the
positive feedback loop that contributes to increased expression of
type I IFN and the induction of an antiviral state. Previous findings
from our group have demonstrated that other ISGs, such as IRF-
7, are up-regulated in response to ATRA treatment during MeV
infection [9]. RIG-I is clearly up-regulated by the combination of
ATRA and MeV in our system (Figure 1A, 1B), therefore its
requirement in mediating the anti-viral effect was further
investigated. We used the Huh-7/7.5 cell culture model of RIG-
I functional loss rather than RNA interference (RNAi) because we
observed that both control and RIG-I specific siRNA (as well as
siRNA specific to other genes in the RIG-I pathway) were
sufficient to induce the expression of RIG-I and other interferon
Figure 1. RIG-I expression is regulated by MeV and ATRA. (A)
U937 cells were infected with MeV at an MOI of 0.1 and treated with
increasing doses of ATRA or DMSO for 24 hours. Some samples were
also treated with 1000 U/mL IFNb for 24 hours, with or without ATRA.
RNA was extracted and analyzed for RIG-I expression by qPCR. Data
presented are representative of three experiments performed in
triplicate (N=3). (B) U937 cells were infected with MeV at an MOI of
0.1 and treated with ATRA or DMSO (1 mM) for 48 hours, or with
2000 U/mL IFNb as a positive control. Samples were analyzed by
western blot for RIG-I and b-actin expression and quantified.
***p,0.001.
doi:10.1371/journal.pone.0022323.g001
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demonstrated in [25,40]).
As expected in the Huh-7/7.5 system, Huh-7.5 cells with non-
functional RIG-I permitted higher levels of viral replication
compared to the RIG-I functional Huh-7 cells (Figure 2A). Levels
of RIG-I mRNA and protein are comparable in both cell lines
(data not shown). ATRA treatment significantly inhibited MeV
production in Huh-7 cells but had no effect in Huh-7.5 cells
(Figure 2A), suggesting that RIG-I has a central role in the
inhibitory effect of retinoids.
To confirm the role of RIG-I in mediating the anti-MeV effect
of ATRA, a RIG-I dominant-negative mutant containing only the
helicase domain of RIG-I (RIG-IC) [23] was transfected into the
ATRA-responsive Huh-7 cells (Figure 2B). RIG-IC has been
previously shown to inhibit Influenza A virus-induced IFN
expression [41]. When Huh-7 cells were infected with MeV and
treated with ATRA, then transfected with the dominant negative
mutant, there was no reduction of MeV replication (Figure 2B).
Blocking RIG-I with RIG-IC in the absence of ATRA treatment
had no significant impact on MeV production (Figure 2B).
Previous studies have demonstrated that RIG-I complementa-
tion in Huh7.5 cells restores the IRF3 pathway rendering the cells
responsive to Sendai virus infection [30]. This demonstrates that
the non-functional RIG-I encoded in the Huh7.5 cells can be
complemented by exogenous expression of the protein. When
wildtype RIG-I is expressed in Huh7.5 cells MeV is inhibited
(Figure 2C).
When RIG-I was blocked in Huh7 cells, the retinoid-MeV anti-
viral effect was lost. Additionally, over-expression of RIG-I can
restore the ability of Huh7.5 cells to inhibit MeV. These data
confirms the requirement of RIG-I for the induction of the
retinoid-MeV anti-viral response.
IFN production up-regulates RIG-I expression in
bystander cells
In different cell culture models MeV can inhibit IFN signaling
to varying degrees and is strain dependent [42]. The tyrosine
residue at the shared position 110 of the V and P proteins is
necessary for MeV to block Stat1 phosphorylation [42,43].
Sequencing of the Chicago stain of MeV used in these experiments
demonstrates a tyrosine a position 110 suggesting that the V
protein is functional [9]. In our previous studies we have
demonstrated increased expression of IFNa1 mRNA by qPCR
and IFNa1 protein expression in the supernatant of cells treated
with ATRA+MeV [9]. We have also demonstrated that IFN
signaling is important for the induction of ISGs in the context of
ATRA treatment and MeV infection [9]. Type I IFN is a key
modulator of the innate immune response to viral infection and,
RIG-I is an ISG [22]. We next sought to determine the role of IFN
signaling in mediating the anti-MeV actions of RIG-I.
In this study, we have confirmed our previous findings
demonstrating the presence of IFNa1 and IFNb in the supernatant
of the ATRA+MeV cells (data not shown). The substantial
induction of RIG-I mRNA by ATRA+MeV was found to be
abrogated when U937 cultures were treated with IFN a/b
receptor blocking antibodies (Figure 3A), in agreement with our
previous findings [9]. A transwell system (Figure 3B) was used to
determine if up-regulation of RIG-I could be induced in bystander
cells, not in contact with the virus, as previously described for
Figure 2. RIG-I necessary for inhibition of MeV by ATRA. (A)
Huh7 and Huh7.5 cells were infected MeV at an MOI of 0.01 and treated
with 1 mM ATRA or DMSO. Whole cell lysates were harvested after
48 hours and viral titers were measured by plaque assay. (B) Huh7 cells
were infected with MeV at an MOI of 0.01 and treated with 1 mM ATRA
or DMSO and transfected with the control plasmid or RIG-I dominant
negative (RIG-IC) expression construct. Whole cell lysates were
harvested after 48 hours and viral titers were measured by plaque
assay. (C) Huh7.5 cells were transfected with the control plasmid or RIG-
I expression construct and infected with MeV at an MOI of 0.01. Whole
cell lysates were harvested after 48hr and viral titers were measured by
plaque assay. Data represent two experiments performed in triplicate
(N=2). **p,0.01, ***p,0.001.
doi:10.1371/journal.pone.0022323.g002
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mRNA in bystander cells exposed to ATRA-treated, MeV-
infected cells in the transwell system (Figure 3C).
The effect of conditioned media from the inner (uninfected)
transwell chamber on RIG-I expression in fresh U937 cells was
analyzed by qPCR. Media conditioned by exposure to ATRA-
treated, MeV-infected cells in the transwell was sufficient to induce
RIG-I expression, whereas media conditioned by exposure to
mock-treated, MeV-infected cells failed to do so (Figure 3C).
Importantly, the up-regulation of RIG-I by inner-chamber media
exposed to both ATRA-treated and MeV-infected cells could be
blocked by antibodies targeting type I IFN a/b receptor
(Figure 3D). These data show that IFN is critical for the induction
of both RIG-I and the retinoid-mediated anti-viral state.
RARa signaling is required for the induction of RIG-I
We have shown that RIG-I is required for induction of the
ATRA-mediated anti-MeV response. RIG-I is both a retinoid-
responsive gene [10] and a cytoplasmic pattern-recognition
receptor that recognizes MeV [22]. To define the role of retinoid
signaling in the induction of RIG-I and the retinoid-induced anti-
MeV state, we used the NB4/R4 cell model (retinoid signaling
responsive versus resistant respectively) [37]. Our group has
recently used this model to demonstrate that RARa signaling is
important for the inhibitory effect of retinoids against MeV [8].
Additionally, we have used this model to demonstrate the
inhibition of MeV by retinoids in the NB4 cells, but not in the
R4 cells [8].
In NB4 cells, ATRA treatment alone had the ability to induce
modest levels of RIG-I mRNA as measured by qPCR (Figure 4A)
and western blot (data not shown). MeV infection of these cells by
itself also induced moderate increases in RIG-I expression
(Figure 4A, data not shown). Similar to the U937 cell model
(Figure 1), the combination of ATRA treatment and MeV
infection yielded a significant level of RIG-I mRNA (Figure 4A,
data not shown). In R4 cells, resistance to retinoid signaling was
first confirmed by demonstrating the inability of ATRA to induce
the expression of RARb, a well documented retinoid responsive
Figure 3. MeV with ATRA induces the soluble factor IFN to elicit the expression of RIG-I. (A) Cells were infected with MeV at an MOI of 0.1
in the presence of 1 mM ATRA or DMSO, and either IFNab-receptor blocking antibodies or isotype control. RNA was extracted at 24 h and RIG-I
expression was measured by qPCR. Data presented are representative of 2 experiments performed in triplicate (N=2). (B) Transwell membrane inserts
with 0.02 mm pores were used to separate the infected cells from the uninfected, bystander cells in the inner chamber [9]. (C) Cells from transwell-free
control wells and the inner chamber bystander cells were harvested after 48 hours and RIG-I mRNA was measured by qPCR. Data presented are
representative of three experiments performed in triplicate (N=3). (D) Supernatants from the control wells and the inner chambers of the transwells
were used to treat fresh U937 cells with either IFNab-receptor blocking antibody or isotype control antibody. Following 24 hours of incubation, RIG-I
expression was assessed by qPCR. Data presented are representative of three experiments performed in triplicate (N=3). **p,0.01, ***p,0.001.
doi:10.1371/journal.pone.0022323.g003
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nor MeV infection alone, nor the combination could induce the
expression of RIG-I mRNA (Figure 4A) or protein (data not
shown). It is important to note that the antiviral effect of ATRA on
MeV in NB4 cells is not due to retinoid induced cell differentiation
as previously demonstrated by CD11b expression [8]. Increased
apoptosis of NB4 cells is also not the cause of the antiviral effect as
demonstrated in our previous work [8]. These observations
demonstrate a requirement of RAR signaling for the induction
of RIG-I.
To confirm the importance of RARa signaling in the expression
of RIG-I, in our original model, we used the RARa antagonist RO
in U937 cells [44]. RO treatment successfully blocked the
induction of RIG-I mRNA observed with the combination of
ATRA treatment plus MeV infection (Figure 4C). This finding
lends further support to the important role of RARa signaling in
the regulation of RIG-I expression.
Retinoic Acid nuclear receptors occupy the RIG-I
promoter
Retinoid signaling is well documented to be important for many
crucial functions in the cell including and, as our data show, the
regulation of RIG-I expression. Therefore, we explored the
recruitment of relevant protein complexes and chromosomal
changes occurring at the RIG-I promoter.
Fourteen putative retinoic acid response elements (RARE) were
identified within 10000 bp of the RIG-I start site using Genomatix
MatInspector software. Predicted RAREs were confirmed using
the consensus sequences previously described [45]. For a DR5/
DR2, the consensus sequence is: not C, G, G/T, not A, G/C, A, 2
or 5 nucleotides, A/G, G, G/T, G/T, C/A, A [45]. Using
Chromatin Immunoprecipitation (ChIP) assays in our U937
model (Figure 5A), we found that both RARa and RXR bind to
the RIG-I promoter (Figure 5B). Retinoid nuclear receptor
binding to an RARE is not dependent on ligand binding [46].
RARa (Figure 5C) and RXR (data not shown) binding to the
RIG-I promoter was not affected by treatment with either ATRA
or IFNb, or by MeV infection.
Activation of RIG-I promoter only upon combination of
MeV and ATRA treatment
To better define the effect of retinoids 6 MeV on the
transcriptional regulation of RIG-I, chromatin remodeling and
the recruitment of proteins associated with transcriptional
activation on the RIG-I promoter were investigated in our U937
model. As an indication of chromatin remodeling, acetylation of
histone H3 (Figure 6A) and histone H4 (data not shown) was
increased following combined ATRA treatment and MeV
infection compared to either manipulation alone and significantly
increased over control. Further, RNA Polymerase II (Pol II) was
strongly recruited to the RIG-I promoter only by IFNb treatment
(positive control) or by the combination of ATRA treatment plus
MeV infection (Figure 6B).
IRF-1 expression is regulated by Measles Virus and ATRA
Regulation of the RIG-I promoter is not limited to retinoic acid
nuclear receptors and traditional transcription factors. Previous
reports have shown that IRF-1 binds the RIG-I promoter and is
important in regulating the IFNb-mediated up-regulation of RIG-
I expression [24]. We therefore used ChIP assays in our U937
model to determine the impact of ATRA 6 MeV on IRF-1
binding to the RIG-I promoter. In our hands, IRF-1 binding to
the RIG-I promoter was readily detected following IFNb
Figure 4. RIG-I expression required RAR signaling. (A) NB4 and
R4 cells were infected with MeV at an MOI of 0.01, treated with 1 mM
ATRA or DMSO and/or treated with 1000 U/mL IFNb. After 48 hours,
samples were harvested and analyzed for RIG-I expression and (B) RARb
expression by qPCR. Data presented are representative of two
experiments performed in triplicate (N=2). (C) U937 cells were infected
at an MOI of 0.1 for 24 hours in the presence of 10 nM ATRA and/or
1000 nM of the RARa-selective antagonist RO 41-5253 (RO). Samples
were analyzed for RIG-I expression by qPCR. Data presented are
representative of three experiments performed in triplicate (N=3).
**p,0.01, ***p,0.001.
doi:10.1371/journal.pone.0022323.g004
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Interestingly, ATRA alone and the combination of MeV and
ATRA also induced IRF-1 binding to the RIG-I promoter in
U937 cells (Figure 6C). Therefore, ATRA alone appears to be
sufficient to recruit IRF-1 to the RIG-I promoter, but is
insufficient for the induction of RIG-I expression. Only IFNb
treatment and the ATRA+MeV combination were successful at
eliciting the expression of both RIG-I mRNA and protein
(Figure 1A and 1B).
In addition to regulation of the RIG-I promoter, several groups
have demonstrated that IRF-1 is induced and activated by ATRA
treatment [11,12,13,14,15,16,17,18,19]. It was therefore of interest
Figure 5. Retinoic acid nuclear receptors bind to the RIG-I
promoter. (A) Diagram of the RIG-I promoter showing the known IRF1
binding site. Arrows represent the site of primers used in ChIP
experiments. (B) RARa and RXR were immunoprecipitated from cells
treated with 1 mM ATRA or DMSO (N=2) (C) U937 cells were infected
with MeV at an MOI of 0.1 and/or treated with 1 mM ATRA or DMSO for
24 hours. 1000 U/ml of IFNb was used as a positive control. These
samples were then immunoprecipitated RARa primary antibodies. The
pulled-down DNA was analyzed by qPCR using primers specific for the
RIG-I promoter as described in the materials and methods. Data
presented are representative of three experiments performed in
triplicate (N=3). *p,0.05, **p,0.01, ***p,0.001.
doi:10.1371/journal.pone.0022323.g005
Figure 6. Activation of RIG-I promoter only upon combination
of MeV infection and retinoid treatment. U937 cells were infected
with MeV at an MOI of 0.1 and/or treated with 1 mM ATRA or DMSO for
24 hours. 1000 U/ml of IFNb was used as a positive control. These
samples were then immunoprecipitated the following primary anti-
bodies (A) Acetylate Histone H3 (B) Pol II (C) IRF-1. The pulled-down
DNA was analyzed by qPCR using primers specific for the RIG-I
promoter as described in the materials and methods. Data presented
are representative of experiments performed in triplicate between two
and three times (N=2–3). *p,0.05, **p,0.01, ***p,0.001.
doi:10.1371/journal.pone.0022323.g006
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ATRA treatment plus MeV infection would have on the regulation
of IRF-1.
In our U937 model, we observed that both IRF-1 mRNA and
protein could be induced by ATRA alone, as well as with the
combination of ATRA treatment and MeV infection (Figures 7A
and 7B). MeV infection alone did not result in detectable changes
in IRF-1 mRNA, but induced modest amounts of IRF-1 protein
(Figures 7A and 7B).
Further studies in our NB4/R4 model revealed this induction of
IRF-1 mRNA by ATRA alone or in combination with MeV
infection to be RARa dependent. When NB4 cells are treated with
ATRA and infected with MeV or treated with ATRA alone there
is a remarkable induction of IRF-1 mRNA (Figure 7C). In R4
cells, neither ATRA treatment nor the combination of ATRA and
MeV was able to induce the expression of IRF-1 mRNA
(Figure 7C).
IRF-1 binding to the RIG-I promoter is required for RIG-I
induction
To investigate the requirement of IRF-1 binding the RIG-I
promoter to induce an antiviral state, we employed synthetic
luciferase constructs targeting the region from 21902 bp to 21b p
of the start site of the RIG-I promoter [23,24] (Figure 7D). The
native construct (pRIGI-full) includes both the known IRF-1
binding site and a predicted RARE (Figure 7D). A second
construct, pRIGI-IRFmut, that contains a mutation in the IRF-1
binding site was used to determine the requirement of IRF-1
binding in the ATRA-mediated transcription of the RIG-I
promoter. Promoter construct experiments were conducted in
HeLa cells for ease of transfection. HeLa cells do not demonstrate
the retinoid-antiviral phenotype due to atypical IFN signaling
(data not shown).
When HeLa cells were transfected with pRIGI-full, we found
that IFNb treatment could induce expression from the RIG-I
promoter, as predicted (Figure 7E). ATRA treatment alone also
strongly induced expression from this promoter construct
(Figure 7E). Although we do not see the expression of RIG-I in
U937 cells (Figure 1A), we have observed the expression of RIG-I
following ATRA treatment alone in NB4 cells (Figure 4A) and in
other cell lines (data not shown). However, neither IFNb nor
ATRA could induce expression from the pRIGI-IRFmut
construct, demonstrating a requirement of activation of the IRF-
1 response element in the RIG-I promoter for the expression of
RIG-I (Figure 7E).
Discussion
Retinol (Vitamin A) is known to have significant clinical benefit
in natural MeV infection, and we have shown that retinoids can
have powerful anti-MeV effects in vitro [2,3,8]. Specifically, we
found that intact retinoid nuclear receptor signaling, as well as
functional type I IFN signaling, are necessary for this inhibitory
effect [8,9]. These studies also revealed that the antiviral impact of
retinoids in our in vitro models was largely realized in cells not yet
productively infected by MeV (so-called ‘bystander cells’ [9]) due
to their exposure to IFN and the resultant high level ISG
expression [9]. In the current work, we sought to explain the
mechanism that leads to the large burst of IFN that protects these
bystander cells from infection. Because RIG-I is an important
component of IFN signaling, and known to be regulated by ATRA
[10,23], we hypothesized that this molecule could act as a bridge
between retinoid and IFN signaling to mediate the inhibition of
MeV.
The RIG-I data presented herein, using a range of in vitro
models, extends our previous observations showing the induction
of IRF-7 by MeV and ATRA. In both studies, type I IFN and
RARa signaling are required [9]. We have now extended these
findings to show that the combination of ATRA treatment and
MeV infection effectively up-regulates RIG-I at the mRNA and
protein levels in both U937 and NB4 cells (Figure 1A, 1B, 4A, 4C),
and that up-regulation of RIG-I expression is required to create
the ATRA-MeV anti-viral state (Figure 2A).
Our previous work had also demonstrated that the antiviral
state created by ATRA treatment during MeV infection occurred
in uninfected bystander cells and was dependent on type I IFN [9].
In the current study, we show that RIG-I is up-regulated in these
uninfected cells (Figure 3C), and that type I IFN secreted into the
media is responsible for inducing the antiviral state (Figure 3A and
3D). When the IFN a/b receptor is blocked with monoclonal
antibodies, the induction of RIG-I is lost (Figure 3A), consistent
with our finding that IFN production is required for the antiviral
state induced by combined ATRA treatment plus MeV infection.
To investigate the role of retinoid signaling in the induction of
RIG-I and its connection to the retinoid-induced MeV anti-viral
state, we used the NB4/R4 cell model (which differ in functional
versus non-functional nuclear retinoid receptor signaling [37]). In
the retinoid-responsive NB4 cells, combined ATRA treatment and
MeV infection resulted in a strong induction of RIG-I mRNA and
protein (Figure 4A, data not shown). In contrast, blunted RAR
signaling in the retinoid-resistant R4 cells prevented the
combination of ATRA treatment plus MeV infection from
inducing RIG-I mRNA expression (Figure 4A, Figure data not
shown). Functional retinoid signaling via RAR is therefore
required for the robust induction of RIG-I by combined ATRA
treatment plus MeV infection.
A number of putative RARE were identified on the RIG-I
promoter, many of had high sequence homology with the
consensus sequences predicted by Balmer and Blomhoff [45].
The retinoid nuclear receptor heterodimer, RAR+RXR, was
shown to bind to the RIG-I promoter (Figure 5B). This binding
was not influenced by ATRA treatment or MeV infection
(Figure 5C and data not shown). These data suggest that
regulation of the RIG-I promoter may be influenced by the
presence of one or more RARE and confirm that RIG-I is a
retinoid responsive gene. Despite binding of the nuclear receptors
to the RIG-I promoter, induction of RIG-I mRNA by ATRA
alone was not observed in U937 cells (Figure 1A) and is only
minimally observed in NB4 cells (Figure 4A). Thus, additional
activating events at the RIG-I promoter may be needed.
Using ChIP, markers of chromatin remodeling, acetylation of
histone 3 (Figure 6A) and acetylation of histone 4 (data not shown)
were seen to increase during ATRA treatment with MeV
infection. These findings indicate that the RIG-I promoter is
rendered conducive to the initiation of transcription through
exposure to combined ATRA treatment plus MeV infection. This
supposition is strongly supported by the recruitment of Pol II to
the RIG-I promoter only under the conditions of ATRA treatment
plus MeV infection (Figure 6B). This regulation of the promoter
correlates with Figure 1A, which shows the induction of RIG-I
mRNA only during combined ATRA treatment and MeV
infection.
The name, Retinoid Induced Gene-I, implies that RIG-I is
indeed retinoid inducible. However, our data reveal only
moderate retinoid responsiveness in some cell lines, such as NB4
(Figure 4A), but no induction whatsoever in other cell lines such as
U937 in response to ATRA (Figure 1A). In the initial microarray
screen performed by Liu et al. that identified the RIG genes,
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PLoS ONE | www.plosone.org 7 July 2011 | Volume 6 | Issue 7 | e22323Figure 7. IRF-1 is regulated by MeV infection and retinoid treatment contributing to the RIG-I antiviral response. (A) U937 cells were
infected with MeV at an MOI of 0.1 and treated with increasing doses of ATRA or DMSO for 24 hours. RNA was extracted and analyzed for IRF1
expression by qPCR. Data presented are representative of three experiments performed in triplicate (N=3). (B) U937 cells were infected with MeV at
an MOI of 0.1 and/or treated with 1 mM ATRA or DMSO for 24 hours. Cells were also treated with 1000 U/ml of IFNb as a positive control. Samples
were analyzed by western blot for IRF-1 and b-actin expression. (C) NB4 and R4 cells were infected with MeV at an MOI of 0.01, treated with 1 mM
ATRA or DMSO and/or treated with 1000 U/mL IFNb. After 48 hours, samples were harvested and analyzed for IRF-1 expression by qPCR. Data
presented are representative of three experiments performed in triplicate (N=3). (D) A schematic of the RIG-I promoter constructs including the full
length construct pRIGI-full and the IRF-binding mutant pRIGI-IRFmut. (E) HeLa cells were transfected with 3 mg of pRIGI-full or pRIGI-IRFmut construct
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induction of RIG-I following ATRA treatment [10]. This
suggested that RIG-I is not directly inducible by ATRA, despite
the presence of putative RARE sequences and readily demon-
strated binding of the nuclear receptors to the RIG-I promoter
(Figure 5A–C).
RIG-I was recently shown to be up-regulated by IFN through
the transcriptional regulation of its promoter by IRF-1 [24]. IRF-1
was the first transcription factor shown to regulate the IFNb
promoter and is also an ISG [47,48]. Although post-translational
modifications have been implicated in controlling its ability to
induce transcription [49,50,51,52], IRF-1 itself is regulated
primarily at the level of transcription [53]. Several groups have
found that ATRA can rapidly induce IRF-1 expression
[11,12,13,14,15,16,17,18,19]. Recently, ATRA has been shown
not only to induce IRF-1, but also increase to its nuclear
localization and binding to specific promoters [18]. This effect
appears to occur through an RARa-dependent pathway [18].
In the present study, we confirmed that IRF-1 is induced by
ATRA alone in U937 cells and that ATRA treatment causes IRF-
1 binding to the RIG-I promoter (Figure 7A–B, Figure 6C). The
level of IRF-1 expression was further increased when ATRA-
treated cells were infected with MeV (Figure 7A). Also, the
induction of IRF-1 appears to be RAR-dependent, as shown by
the lack of expression in R4 cells deficient in retinoid signaling
(Figure 7C). IRF-1 binding to the RIG-I promoter in ATRA-
treated cells was not influenced by MeV infection (Figure 6C).
However, indicators of transcriptional activation, such as recruit-
ment of Pol II, as well as the presence of RIG-I mRNA, were only
observed following the combination of ATRA treatment and MeV
infection in U937 cells (Figure 6B and 1A). In our hands, IFNb
treatment was sufficient to induce IRF-1 expression, IRF-1
binding to the RIG-I promoter and RIG-I expression. These
data support the findings of Su et al. and suggest that IRF-1 is
primarily responsible for the IFN-induced expression of RIG-I
(Figures 7A-B and data not shown).
Since both RIG-I and IRF-1 are induced by combined ATRA
treatment and MeV infection, but RIG-I appears to be essential
for the antiviral response, we examined the requirement of IRF-1
for the induction of RIG-I using a RIG-I promoter construct
containing both a hypothetical RARE and the IRF-1 response
element (IRE) [24] (Figure 7D). The RIG-I promoter initiated
expression following both IFN and ATRA treatment (Figure 7E)
but neither treatment could initiate promoter expression when the
IRE was mutated (Figure 7E). These findings show that the RIG-I
promoter is regulated by ATRA in an IRF-1-dependent manner.
Lou et al. have recently reported that the induction of retinoid-
induced gene G (RIG-G) is also mediated primarily through IRF-1
[54].
Our studies to date lead us to propose a model in which
transcriptional up-regulation of RIG-I acts as a critical step in the
inhibition of MeV by ATRA. In particular, we have demonstrated
that when a cell population is infected with MeV at a low
multiplicity of infection (MOI) and treated with ATRA, the initially
uninfectedcells areprotected from productive infection by exposure
to large amounts of IFN and the up-regulation of ISG expression as
a bystander effect [9]. We hypothesize that initially uninfected cells
exposed to retinoids and media conditioned by infected cells are
crucial forthelarge burstof IFN leading toinductionof ananti-viral
state. In these cells ATRA also up-regulates IRF-1 expression and
binding to the RIG-I promoter. This leads to a ‘priming’ of the
RIG-I promoter to respond rapidly to other stimuli. Retinoids have
been implicated in the regulation of a number of ISGs including
IRF-1 [11,12,13,14,15,16,17,18,19] and RIG-I [10]. Both of these
genes have RAREs in their promoter regions. The proximity of the
IRF-1 response element to possible RAREs in the RIG-I promoter
suggests that there may be interaction between IRF-1 and RARs
binding to the RIG-I promoter and this is currently under
investigation. A second signal may be required to activate
transcription in the U937 model, as has been observed for the
Dif2 promoter [55].
Even in the absence of ATRA, MeV infection was able to
induce some production of type I IFN in our cell culture models
[9]. This likely occurs through detection by RIG-I early in
infection, as the uncapped leader RNA of the virus is a known
RIG-I ligand [22]. We hypothesize that IFN produced by these
initially infected cells provides the second signal to the uninfected
cells, allowing them to transcribe large amounts of RIG-I. In our
U937 model, ATRA alone does not induce RIG-I mRNA but it
can work in combination with IFNb to induce high levels of RIG-I
comparable to those seen with the combination of ATRA
treatment and MeV infection (Figure 1A).
Measles-associated mortality and morbidity is correlated with
both the infecting inoculum [56] and the extent of viral replication
[57]. Early control of MeV replication may therefore influence the
severity of disease. The ability of retinoids to induce RIG-I leading
to the expression of type I IFN could contribute to the antiviral
state and limit total body viral burden. We are currently
investigating the effect of retinoids on other paramyxoviruses.
Our current and previous studies use a variety of cell culture
and primary tissue, additionally; retinoids have been implicated in
T lymphocyte proliferation and cytotoxicity [58], B cell prolifer-
ation [59] dendritic cell migration [60]. The combination of
retinoids and MeV in these primary cells will be investigated in a
small animal model. Our current studies do not address the timing
of retinoid treatment during clinical MeV infection however. A
small animal model is required to investigate the role of RIG-I
during established MeV infection [61].
In conclusion, we have demonstrated that RIG-I expression is
regulated by ATRA during MeV infection and is required for the
anti-MeV state. We have also shown that IRF-1 is regulated by
ATRA and plays a central role in mediating the anti-MeV effects
of retinoids. IRF-1 is recruited to the RIG-I promoter under the
influence of ATRA alone, and is required for the induction of
RIG-I. In these models systems therefore, ATRA inhibits MeV
replication through the RARa-dependent regulation of RIG-I and
IRF-1 and via an IFN feedback loop.
Materials and Methods
Cells, reagents and viruses
All cell cultures were maintained at 37uC in a 5% CO2
humidified incubator. U937, NB4 and R4 cells were cultured as
previously described [8]. The human hepatoma cell lines Huh7
and Huh7.5 (courtesy C. Richardson, Dalhousie University,
Halifax, NS) were maintained in Dulbecco modified Eagle
medium (Wisent, St-Bruno, QC) supplemented with 10% heat-
inactivated fetal bovine serum (FBS; Wisent, St-Bruno, QC) and
0.1% gentamicin. HeLa (ATCC, #CCL-2) cells were maintained
in Dulbecco modified Eagle medium (Wisent, St-Bruno, QC)
and 0.5 mg of Renilla control. The cells were then treated with 1 mM ATRA or 1000 U/ml of IFNb for an additional 24 hours. Samples were then
analyzed for dual-luciferase expression. *p,0.05, **p,0.01, ***p,0.001.
doi:10.1371/journal.pone.0022323.g007
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QC) and 1% penicillin/streptomyocin. All-trans retinoic acid
(ATRA) (Sigma-Aldrich Fine Chemicals, ON) was kept as a stock
solution at 10
22 M in 100% DMSO and further dilutions were
performed in media. All retinoids were stored in opaque
eppendorf tubes at 280uC and were handled in low-light
conditions. The Chicago-1 MeV strain is a tissue culture-adapted
genotype D3 virus (courtesy of W. Bellini, CDC, Atlanta, GA).
MeV stock was grown by infecting Vero cells (ATCC, #CCL-81)
at a multiplicity of infection (MOI) of 0.001 at 33uC in a Celligen
Plus Bioreactor System (New Brunswick Scientific, Edison, NJ).
Cell lines were infected with MeV and treated with ATRA as
previously described [9] using the specific MOIs and time points
indicated in the figure legends.
Quantitative RT-PCR
RNA was extracted using Trizol (Invitrogen, Life Technologies)
as per the manufacturer’s instructions, and treated to remove
possible genomic DNA contamination with Turbo DNAse
(Ambion, Austin, TX). For experiments in which antibodies were
used to block type I IFN signaling, an RNeasy Mini kit was used to
extract RNA (Qiagen, Mississauga, ON). Equal quantities of RNA
were reverse-transcribed into cDNA for qPCR analysis using
random primers. FAM-labeled TaqMan primer-probe assays for
the following genes were obtained from ABI (Foster City, CA):
RIG-I, RARb and IRF-1. The level of gene expression in
untreated cells was used for calibration. Vic-labeled hGAPDH was
used as the endogenous control.
Western blotting
Cells were infected with MeV and/or treated with ATRA for
indicated time periods washed in PBS and incubated in RIPA
buffer on ice for 20 minutes (0.15 M NaCl, 0.05 M Tris-HCL, 1%
Triton-X 100, 0.5% sodium deoxycholate, 0.1% SDS, 1 mM
sodium orthovanadate). A protease inhibitor cocktail (Roche,
Laval, QC) was diluted in RIPA buffer according to the
manufacturer’s instructions. The samples were pre-cleared, equal
amounts of protein were separated by SDS-PAGE gel and
transferred to PVDF membranes (Biorad, Hercules, CA). The
membranes were incubated in 5% non-fat milk or 5% BSA for
1 hour and incubated overnight at 4uC with primary antibody.
Primary antibodies used were against RIG-I (1/1000, courtesy of
J. Hiscott, McGill University), IRF1 1/200, (Santa Cruz
Biotechnology, CA, USA) and b-actin (1/10000, Sigma). Follow-
ing overnight incubation, membranes were washed three times for
10 minutes in TBS/0.1% Tween, incubated with secondary
antibody (1/10000, GE Healthcare) at room temperature for 60
minutes, and washed three times for 10 minutes. The peroxidase-
conjugated secondary antibodies were developed using a chemi-
luminescence kit according to the manufacturer’s instructions (GE
Healthcare).
Transwell and blocking antibody experiments
Transwell experiments (TW) were performed as previously
described [9]. Briefly, cells infected at a low MOI are plated in 6-
well plates. Transwell inserts were placed on top (0.02 mm pore
membrane inserts, Nunc, Rochester, NY), and uninfected cells
were placed in the inner chamber. The final overall MOI of the
total well (inner plus outer chamber) was 0.01, and wells were
either treated with DMSO or 1 mM ATRA. Control wells without
membrane inserts were plated in the same manner, either with or
without MeV, and with either DMSO or 1 mM ATRA. Cells were
collected following 48 hours incubation and analyzed for gene
expression by qPCR. Supernatants were also collected and used to
treat fresh U937 cells. These fresh cells were pre-treated with anti-
IFNAR2 blocking antibody (20 mg/mL, PBL Biomedical Labora-
tories, Piscataway, NJ) or isotype control antibody for one hour,
and treated with these antibodies for the following 24 hours along
with the conditioned media from the TW experiments. The
blocking-antibody protocol was used to study the effect of IFN in
the context of cells directly infected with MeV and/or treated with
ATRA. These samples were analyzed by qPCR for the expression
of RIG-I.
Chromatin immunoprecipitation (ChIP)
ChIP assays were carried out using a modified Upstate
Biotechnology protocol as previously described [52]. Briefly,
4610
6 cells were infected with MeV at an MOI of 0.1 and/or
treated with 1 mM ATRA or DMSO for the indicated time periods.
These cells were fixed in 1% formalin, lysed by sonication, and
precleared with 80 mL of protein A agarose beads (Upstate,
Millipore, Billerica, MA) for 1 hour in immunoprecipitation buffer
(0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM Tris,
16.7 mM NaCl, 0.01 mg/ml aprotinin, 0.01 mg/ml leupeptin,
0.5 mM PMSF, 5 mM NaF). The samples were immunoprecipi-
tated overnight with the appropriate antibody. Antibodies against
the following proteins were used: IRF1 (5 mg Ab, Santa Cruz
Biotechnology), RARa (2 mg Ab, Santa Cruz Biotechnology), Ac-
Histone H3 (5 mg Ab, Upstate Millipore), and Pol II (5 mg Ab,
Upstate Millipore,). Complexes bound to these antibodies were
pulled down by 60 mL protein A agarose beads during a 4 hour
incubation, and then washed in buffers of increasing stringency and
eluted in elution buffer (1% SDS, 50 mM Tris, 10 mM EDTA).
NaCl at 200 mM was used to reverse cross-linking at 65uC
overnight. DNA extraction was performed using the QIAquick kit
(QIAGEN, Mississauga, ON). qPCR analysis for the RIG-I
promoter was performed using the following primers: forward
(CAGCCGACGTGGGAGAACT), reverse (GCGCTAACGTT-
TAGACACAGTAAAAT). Input DNA was used as an endogenous
control. Treatments were performed in duplicate, and qPCR
amplifications were performed in triplicate.
Luciferase assay
RIG-I promoter constructs (courtesy P. Fisher, Colombia
Univeristy, New York, NY) were cloned into the pGL3-basic
vector and mutated as described [24]. Two RIG-I constructs were
utilized: a ‘full-length’ promoter construct (pRIGI-full) including -
1902 bp to -1 bp and a site directed mutatgenesis of the IRF-
binding site mutant of the full-length construct (pRIGI-IRFmut).
HeLa cells seeded at 1.5610
5 cells/mL were transfected 12 hours
later with 3 mg of luciferase expression construct and 0.5 mgo f
control Renilla construct using 3:1 ratio of FuGENE 6 (Roche,
Toronto, ON) as per the manufacturer’s instructions. Samples
were treated with 1 mM ATRA or DMSO or 1000 U/mL IFNß
for 24 hours and analyzed for luciferase expression using the Dual
Luciferase Assay System (Roche, Toronto, ON). Luciferase
activity was normalized to Renilla expression and samples were
analyzed in triplicate.
Dominant negative transfection
Huh 7 cells were seeded at 1610
5cell/mL were infected
12 hours later with MeV MOI 0.01 and/or treated with 1 mM
ATRA or DMSO. Post infection 3 mg of the dominant-negative
RIG-I construct (RIG-IC) (gift from J. Hiscott) or empty vector
were transfected using 3:1 ratio of FuGENE 6 (Roche, Toronto,
ON) as per the manufacturer’s instructions. 48 hours post
infection the cells and supernatants were quantified using plaque
assay as previously described [8].
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Huh 7.5 cells were seeded at 1.56105cell/mL were transfected
with 3 mg of the RIG-I construct in a pcDNA3 plasmid (gift from
J. Hiscott) or empty vector using a 3:1 ratio of FuGENE 6 (Roche,
Toronto, ON) as per the manufacturer’s instructions. 18 hours
post-transfection cells were infected with MeV MOI 0.01.
48 hours post infection the cells and supernatants were quantified
using plaque assay as previously described [8].
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